Evolution of the Average Target: RH

Evolution of the Target Price: RH

Changes in Analyst Recommendations: RH

31b559ca787.SuQW9U7b3YWCt89h7n7aXr_fBllOOkLTWsLBoDCHH6E.LqhkuCCY5M3TwYULoj-2DYjycgZ9XQ2gAqyuyED-b5F9yVDEP-uU9NrGig~4450452c6941df2a5e91c4118f41028a
07-08 Goldman Sachs Upgrades RH to Neutral From Sell, Lifts Price Target to $155 From $86 MT
06-09 RH Q1 Unlikely to Show Business Inflection, UBS Says MT
06-09 UBS Adjusts Price Target on RH to $155 From $160, Maintains Neutral Rating MT
04-02 Guggenheim Lowers Price Target on RH to $200 From $275, Keeps Buy Rating MT
04-01 RH Facing Near-Term Challenges From Execution, Supply Chain Issues, Morgan Stanley Says MT
04-01 Morgan Stanley Lowers Price Target on RH to $240 From $275, Keeps Overweight Rating MT
12-20 JPMorgan Cuts Price Target on RH to $225 From $275, Maintains Overweight Rating MT
12-12 Stifel Downgrades RH to Hold From Buy, Adjusts Price Target to $165 From $320 MT
02/10/25 William Blair Downgrades RH to Market Perform From Outperform MT
12/09/25 Telsey Advisory Downgrades RH to Market Perform From Outperform, Adjusts Pt to $220 From $255 MT
25/06/25 RH Shares Fall After Goldman Sachs Downgrade MT
24/06/25 Goldman Sachs Downgrades RH to Sell From Neutral, Adjusts Price Target to $179 From $199 MT
05/06/25 UBS Adjusts RH Price Target to $215 From $235, Maintains Neutral Rating MT
15/05/25 BofA Securities Adjusts Price Target on RH to $172 From $144 MT
08/04/25 RH Cash Flow, Demand Guidance Eases Tariff Concerns, Wedbush Says MT
03/04/25 RH Earnings Troubles Exacerbated by Trump Tariffs, Wedbush Says; Shares Down Pre-Bell MT
03/04/25 Wedbush Adjusts RH Price Target to $250 From $350, Maintains Outperform Rating MT
03/04/25 UBS Adjusts Price Target on RH to $235 From $250, Keeps Neutral Rating MT
27/03/25 RH Could See Solid Sales, Soft Margins for Fiscal Q4, Wedbush Says MT
26/03/25 BofA Securities Cuts RH Price Target to $410 From $510, Maintains Buy Rating MT
26/03/25 Wedbush Cuts Price Target on RH to $350 From $500, Keeps Outperform Rating MT
21/03/25 UBS Adjusts Price Target on RH to $250 From $440, Keeps Neutral Rating MT
30/01/25 Goldman Sachs Upgrades RH to Neutral From Sell, Raises Price Target to $374 From $261 MT
13/01/25 Morgan Stanley Upgrades RH to Overweight From Equalweight, Raises Price Target to $530 From $435 MT
08/01/25 Barclays Upgrades RH to Overweight From Equalweight, Raises Price Target to $515 From $383 MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
-10.93%
-4.58%
+15.23%
+32.92%
+45.64%
+11.36%
+25.04%
+13.46%
-3.69%
+39.7%
Average +16.42%
Weighted average by Cap. +3.53%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
190.26USD
Average target price
169.47USD
Spread / Average Target
-10.93%
High Price Target
270.00USD
Spread / Highest target
+41.91%
Low Price Target
90.00USD
Spread / Lowest Target
-52.70%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

Goldman Sachs
UBS
Guggenheim
Morgan Stanley
JPMorgan Chase
Stifel Nicolaus
William Blair & Co.
Telsey Advisory Group
BofA Securities
Wedbush
Barclays
Baird
Jefferies & Co.
BNP Paribas Exane
TD Cowen
Wells Fargo Securities
Loop Capital
Citigroup
Cowen
Gordon Haskett
J.P. Morgan Chase
Trader
Investor
Global
Quality
-
ESG MSCI
BB
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
190.26USD
Average target price
169.47USD
Spread / Average Target
-10.93%

Quarterly revenue - Rate of surprise